What were the findings of the ADVANCE collaborative group?
The ADVANCE collaborative group found that the addition of perindopril plus indapamide to current therapy used in patients with type 2 diabetes and high cardiovascular risk reduced the rate of major or microvascular events. Further, in a secondary analysis, kidney events (mostly measures of appearance or worsening of urinary AER) were less frequent with a lower achieved BP at the follow-up visit. The absolute risk reductions for cardiovascular and kidney end points associated with active treatment (irrespective of BP) were greater among patients with CKD 3 5 than among patients with CKD 1 2. 